GENETICS OF COMPLEX DISEASES: METHODOLOGICAL TOOLS

STATISTICAL METHODS TO IDENTIFY GENETIC FACTORS IN HUMAN DISEASES

M1 Geniomhe

2024-2025

Valérie Chaudru valerie.chaudru@univ-evry.fr Elisabeth Petit-Teixeira


AIM OF THE COURSE



Human genome : ~3 billion base pairs (A, C, T, G)

=> Overall similarity across human genomes : 99.6%

=> Genetic diversity ≈0.4%




Epidemio-genetics methods aim to identify new genetic factors based on genetic diversity in complex human diseases

Scoring

50% CC (online Multiple Choice Questions) – end of the course

50% Exam – exam's week

RISK FACTORS IN HUMAN DISEASES



> Monogenic diseases / Multifactorial diseases

Masson, 2004

MONOGENIC DISEASES VS MULTIFACTORIAL DISEASES

| Familial aggregation: the occurence of diesease in multiple members of a family, across generations (inheritance) | Monogenic Pedigree | Complex (multifactorial) |
|---|--|--|
| Disease frequency | Mendelian entities -> One genetic factor =/= Only one mutation in the patient. Rare | Medium / High If high, environmental factors assume the |
| Familial aggregation | High (hereditary diseases) | function of mendelian entities (somewhat) Low (except in 5-10% of cases) |
| Nb of genes | 1 Mendelian entity (≠ mutations of the gene) | Multiple (interactions between genes) |
| Penetrance | penetrance 0.8 < 1 High (but incomplete) | Low (except if Mendelian entity) |
| Environment effect | Low (treatment aid) | Medium / High (interactions with genes) |


Definitions for a genetic risk factor: If complete penetrance <=> P = 1

Compare observed cases of familial disease to decide penetrance of disease; you cannot look at random samples, only families

- Penetrance = P([affected]/at-risk genotype)

- Phenocopy = P([affected]/non at-risk genotype)

FOCUS ON THE SPECTRUM OF GENETIC FACTORS IN COMPLEX DISEASES




EXAMPLE OF MONOGENIC DISEASE: PHENYLKETONURIA

+ DISEASE

- Inability to properly convert phenylalanine (one of the amino acids found in food) into tyrosine
 - > accumulation of toxic compounds for the brain and significant mental retardation from childhood
- Incidence : ≈ 1/16000
- ◆ GENETIC FACTOR Mendelian entity (Complete/Absolute) penetrance
 - Gene PAH (phenylalanine hydroxylase) chrom. 12 recessive trans.
 - \approx 500 mutations identified Confounding factors but not the "driver" mutations of the disease; are an after effect.
 - Mut. cause enzyme deficiency
 - High penetrance
 - \triangleright if dietary treatment at birth --> penetrance ≈ 0

EXAMPLE OF A COMPLEX DISEASE: BREAST CANCER



Missing heritability = part of the genetic component not yet identified


(While some women observe high penetration in their family, we do not know what the mendelian entity is to drive this inheritance in those extreme cases.)

=> Use of genetic variability between individuals and statistical methods to minimize missing heritability

GENETIC MARKERS FOR STUDYING GENETIC DIVERSITY

Most commonly used genetic marker for disease analysis is:

SNV = single nucleotide variant:
 DNA sequence variation in which a single nucleotide — A, T, C or G — differs between members of the same species




SNP = single nucleotide polymorphism:
 SNV occurring commonly within a population (> 1%)


Small insertions/deletions (indels)




Large copy number variants (CNVs)
 >1 kb



SEQUENCING AS TOOL TO IDENTIFY GENETIC MARKERS



HOW IS USED THE GENETIC MARKERS INFORMATION?



WHAT DID I REMEMBER ? (1)









Entrez le code d'événement dans le bandeau supérieur





Envoyez @XELTEB au 06 44 60 96 62





Désactiver les réponses par SMS


HISTORY OF METHODS TO IDENTIFY GENETIC FACTORS (non exhaustive)

to calculate concordance: # of matching genetic factors between twins, over total genetic factors possible

compare phenotypic concordance against control Comparison of disease Is there familial clustering? risk in relatives of cases => Recurrence risk vs risk in population monozygotic twins by definition should have the same genetic components E for environmental factors Pheno. Concordance Rate (blue) MZ: Monozygotic..... Is there genetic component? => Twin studies + others... If PCR_{M7}<1 => Influence of E If PCR_{D7}< PCR_{M7} => Influence of G Localisation of the G factor? Disease gene close to => Linkage analysis which genetic marker? Linkage region Not all alleles are susceptibility; increase disease risk! SNP1 SNP2 SNP3 Causal variant? See which genetic factors f(allele1 SNP3) > in compound disease risk cases than in controls? => Association Analysis Is genotypic risk on Search for interactions? disease depends on E? => GxG and/or GxE 12

SOME EXAMPLES OF GENETIC ANALYSES


Linkage analyses




positional cloning or functional studies of candidate genes

Location of disease genes on the genome


Transcriptomic analyses








Identification of groups of genes (rows) over or under expressed in sample subgroups (columns) Identification of new genetic factor in a human disease



Genetics of Complex Diseases: Methodological Tools

PART 1

GENETIC ASSOCIATION ANALYSES



PREFERENTIALLY USED MARKERS: SNP

SNP = Single Nucleotide Polymorphism

- => very abundant and evenly distributed in the human genome ~ 1 SNP every 100-300 bp
- => Most SNPs are located in non-coding regions and have no direct impact on an individual's phenotype
- => Some SNPs may be in coding regions and have functional consequences

Example:

Sequence 1: ...CTGACTCCTGAGGAGAAG...
Sequence 2: ...CTGACTCCTGTGGAGAAG...

MAIN STRATEGIES

Positional cloning

Linkage analyses




Refine the region by genotyping more markers (SNPs) in linkage region (or in candidate genes of the linkage region)



Association studies to search for the causal variant

Genome-Wide Association studies (GWAs)

Genotyping of 500,000 - 1 million SNPs covering the genome in thousands of cases / controls



Discovery of new susceptibility genes without conducting linkage analyses

Test

| | Samples | Methodology |
|---|--------------------|-----------------------------|
| | Unrelated subjects | χ² or Regressive models |
| , | Nuclear families | Transmission Disequilibrium |

(parents + offsprings)

Mathadalas

 (TDT)

ASSOCIATION ANALYSES

SEARCH FOR CAUSAL VARIANTS

-

POPULATION-BASED ASSOCIATION ANALYSES

DESIGN OF CASES-CONTROLS ASSOCIATION STUDY


* Aim : search for causal genetic variant

SNP1 SNP2 SNP3 SNP4 SNP5 SNP6

Candidat gene

Studied sample

Cases (affecteds) and controls (unaffecteds) - all unrelated



For a given marker (SNP):

- a) Are allele frequencies ≠ between cases and controls?
- b) Are genotype frequencies \neq between cases and controls?

For a set of marker (SNPs):

c) Are haplotype frequencies \neq between cases and controls?

FEW WORDS ON QUALITY CONTROLS (1)

The main (non-exhaustive) steps for data quality control are :

- Deletion of SNP with % of missing genotypes (00 in the table) > threshold
 Ex: call rate < 95% => SNP with > 5% of missing genotypes => removed
- > Deletion of individuals with % of missing genotypes (00 in the table) > threshold Ex: call rate < 95% => individuals with > 5% of missing genotypes => removed

| | SNP1 | SNP2 | SNP3 | SNP4 | SNP5 | SNPn' | |
|-------|------|------|------|----------|------|-----------|--------------|
| Ind 1 | 11 | 11 | 12 | 00 | 22 | 11 | |
| Ind 2 | 00 | 00 | 22 | 00 | 00 | 00 | ⇒ DEL |
| Ind 3 | 11 | 22 | 12 | 12 | 12 | 22 | |
| Ind 4 | 22 | 12 | 22 | 00 | 11 | 11 | 1=ref |
| ••• | | | | | | | 2=alt |
| Ind n | 12 | 12 | 22 | 00 | 12 | 11 | |
| | | | | ↓ | | | |

DEL

FEW WORDS ON QUALITY CONTROLS (2)

The main (non-exhaustive) steps for data quality control are :

- > Deletion of genetic markers (SNP) « rare »

 Ex: SNPs with MAF (Minor Allele Frequency) <5% removed
- > Deletion of genetic markers (SNP) which do not verify the Hardy-Weinberg (H-W) model in controls

Conformity test to the H-W model (chi-square test)

H0: H-W verified $(f(11)=f(1)^2 ; f(12)=2*f(1)*f(2) ; f(22)=f(2)^2)$

H1: H-W not verified

| ì | _ | | | | | | | | |
|---|---|----|---|---|-----|------|----|-----|---|
| | H | ro | m | 0 | DS. | . CC |)U | nts | : |

$$f(1) = (2*n1 + n2)/(2*N)$$

$$f(2) = (2*n3 + n2)/(2*N)$$

| Genotypes : | 11 | 12 | 22 | Total |
|--------------------------|---------------------|---------------|---------------------|-------|
| Observed counts | n1 | n2 | n3 | N |
| Expected counts under H0 | N*f(1) ² | N*2*f(1)*f(2) | N*f(2) ² | N |


 χ^2 (nb categories – 1 - (nb all. freq – 1)) = Σ_{cats} (obs count -exp count)² / exp count

FEW WORDS ON QUALITY CONTROLS (3)


The main (non-exhaustive) steps for data quality control are :

> To check if cases and controls are genetically homogeneous for « neutral » SNPs

Principal Componant Analysis (PCA)




Cases (yellow dots) & controls (red dots) are pooled => homogeneity => good



Cases (yellow dots) & controls (purple dots) are not pooled => heterogeneity => not good

POPULATION STRATIFICATION


A population can be composed from ≠ sub-population having ≠ allele frequencies



- \$\top Consequence of pop. stratification : false positive association
- Remedies to pop. stratification by matching cases and controls by ethnic background

 Then use adapted test: Mantel-Haenszel or adjusted logistic regression by stratum...

USE OF LINKAGE DISEQUILIBRIUM



Measures that can be used:

- $-r^2*100$
- D'*100

- 1. A priori to select a SNP (tagSNP) in a linkage disequilibrium block if a huge number of SNPs are analysed
- 2. A posteriori to search for the causal variant

LINKAGE DISEQUILIBRIUM (LD) DEFINITION

- Gametic disequilibrium : Preferential association between alleles taken at ≠ loci
- Linkage disequilibrium : Gametic disequilibrium that persists due to a genetic linkage (the 2 loci are close)
- * Examples : SNP A with 2 alleles : A1 (p1=0.1) et A2 (p2=0.9)
 SNP B with 2 alleles : B1 (q1=0.3) et B2 (q2=0.7)

| Equilibrium | | Disequilibrium | | |
|------------------------------|--------------|--|---------------------------------|--|
| Random association o | of alleles | Preferential association between alleles | | |
| Haplotypic freq. | Example | Haplotypic freq. | Example if A1 is always with B1 | |
| $f(A_1,B_1) = f(A_1)*f(B_1)$ | 0.1*0.3=0.03 | $f(A_1,B_1) \neq f(A_1)^*f(B_1)$ | 0.1 | |
| $f(A_1,B_2) = f(A_1)*f(B_2)$ | 0.1*0.7=0.07 | $f(A_1,B_2) \neq f(A_1)^*f(B_2)$ | 0 | |
| $f(A_2,B_1) = f(A_2)*f(B_1)$ | 0.9*0.3=0.27 | $f(A_2,B_1) \neq f(A_2)^*f(B_1)$ | 0.2 | |
| $f(A_2,B_2) = f(A_2)*f(B_2)$ | 0.9*0.7=0.63 | $f(A_2,B_2) \neq f(A_2)^*f(B_2)$ | 0.7 | |

EXAMPLE: POPULATION IN LD FOR 2 SNP

If 2 linked loci studied: - A with 2 alleles: A1 (p1=0.1) et A2 (p2=0.9)
- B with 2 alleles: B1 (q1=0.2) et B2 (q2=0.8)

Population n°1 (n=50) N=40

⇒ Linkage disequilibrium (2 under-represented haplotypes)

Observed frequency of haplotypes:

$$- f(A1,B1) = (2*5) / 100 = 0,1$$

$$- f(A2, B1) = (2*5) / 100 = 0,1$$

$$-f(A2, B2) = (2*40) / 100 = 0.8$$

$$-f(A1, B2) = 0$$

Expected frequency if no LD:

$$- f(A1,B1) = f(A1) * f(B1) = 0.1*0.2 = 0.02$$

$$-f(A2, B1) = 0.9*0.2 = 0.18$$

$$-f(A2, B2) = 0.9*0.8 = 0.72$$

$$-f(A1, B2) = 0.1*0.8 = 0.08$$

EXAMPLE: POPULATION AT EQUILIBRIUM FOR 2 SNP

If 2 linked loci studied: - A with 2 alleles: A1 (p1=0.1) et A2 (p2=0.9) - B with 2 alleles: B1 (q1=0.2) et B2 (q2=0.8)

Observed frequency of haplotypes:

$$- f(A1,B1) = (2*1) / 100 = 0.02$$

$$- f(A2, B1) = (2*9) / 100 = 0.18$$

$$-f(A2, B2) = (2*36) / 100 = 0.72$$

$$-f(A1, B2) = (2*4) / 100 = 0.08$$

Expected frequency if no LD:

$$- f(A1,B1) = f(A1) * f(B1) = 0,1*0,2 = 0,02$$

$$- f(A2, B1) = 0.9*0.2 = 0.18$$

$$-f(A2, B2) = 0.9*0.8 = 0.72$$

$$- f(A1, B2) = 0.1*0.8 = 0.08$$

Population n°2 (n=50) ⇒ Linkage equilibrium

(random association between alleles)

MEASURES OF LINKAGE DISEQUILIBRIUM

```
Consider 2 bi-allelic genes: A with 2 alleles: A1 (p1) et A2 (p2)
                                        B with 2 alleles: B1 (q1) et B2 (q2)
\triangleright \Delta : \Delta = f(A1, B1) - f(A1) f(B1)
         Δε [-0.25, +0.25]
\triangleright D': D' = \triangle/D_{max} (Lewontin, 1964)
         où D_{max} = Min \{p_1q_2, p_2q_1\} si \Delta > 0
                       Min \{p_1q_1 \quad p_2q_2\} si \Delta < 0
         D' ε [-1, +1]
> r^2 : r^2 = \Delta^2 / (p_1 p_2 q_1 q_2)
                                                     (Hill et Robertson, 1968)
            r^{2} \epsilon [0, +1]
```

EXAMPLE OF CALCULATION OF LD MEASURES

* Allelic and haplotypic frequencies at the 2 loci studied

$$f(A1, B1) = 0.05$$
 $f(A2, B1) = 0.25$ $f(A1, B2) = 0.05$ $f(A2, B2) = 0.65$

- Measures of LD
 - Δ_{A1B1} = f(A1, B1) f(A1) * f(B1) = 0.05 0.1*0.3 = 0.02
 - $D'_{A1B1} = \Delta_{A1B1}$ / min {0.1*0.7; 0.9*0.3} = 0.02/0.07 = 0.29
 - $r^2 = \Delta^2_{A1B1} / (0.1*0.9*0.3*0.7) = 0.02^2/0.0189 = 0.02$

• If equilibrium : •
$$\Delta = 0$$

• D' = 0
• r = 0

High LD if
$$r^2$$
 (or D') > 0.8

WHAT DID I REMEMBER ? (2)













Envoyez @NHAUGF au 06 44 60 96 62



Désactiver les réponses par SMS

TEST FOR ALLELIC ASSOCIATION

* Contingency table for a di-allelic locus

Assume a multiplicative effect of allele

| | Cases | Controls | total |
|----------|------------|----------|-------|
| Allele 1 | O11=a | O12=b | R1 |
| Allele 2 | O21=c | O22=d | R2 |
| total | <i>C</i> 1 | C2 | N |

Test for association

• HO: No allelic association

H1: Association

• Homogeneous χ^2 (on 1-df)

$$\chi^2 = \Sigma [(Oij - (Ri*Cj)/N)]^2 / ((Ri*Cj)/N)$$

$$df = (no row -1) * (no column -1)$$

Allelic risk (2 vs 1) estimated by the odds ratio (OR)

$$OR = (c*b) / (a*d)$$

95% CI =exp [
$$ln(OR) \pm 1.96*\sqrt{var(lnOR)}$$
]


$$Var(InOR) = \frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}$$

EXAMPLE OF ALLELIC ASSOCIATION TEST

Search for an association between 1 SNP (A and B alleles)

and a disease

Observed count:



* Allelic risk for B allele:

$$OR_{B/A} = (265 \times 380) / (175 \times 200) = 2.88$$

* Confidence Interval (CI):

$$CI = [2,23-3,72] \leftarrow CI \text{ for } ln(OR) : ln(2,88) \pm 1.96 \sqrt{(0,017)}$$

Homogeneity test:

•
$$\chi^2 = 66.85$$

• Nb of degrees of freedom = (2-1) * (2-1) = 1

Ho rejected

=> association

TEST FOR GENOTYPIC ASSOCIATION

* Table for a di-allelic locus and a general genotypic model

| | Cases | Controls | total | OR | 95% <i>C</i> I |
|-------------|------------|----------|-------|-------|---|
| Genotype 11 | O11=a | O12=b | R1 | - | - |
| Genotype 12 | O21=c | O22=d | R2 | cb/ad | $exp[ln(OR)\pm1.96\sqrt{(1/a+1/b+1/c+1/d)}]$ |
| Genotype 22 | 031=e | O32=f | R3 | eb/af | $exp[ln(OR)\pm 1.96\sqrt{(1/a+1/b+1/e+1/f)}]$ |
| total | <i>C</i> 1 | C2 | N | | |

- ϕ Test of genotypic association with homogeneity χ^2 (on 2-df)
- \$ Genotype 11 is considered as the baseline
- Other genotypic coding
 - Dominant model: pool 12+22 --> 2x2 table
 - Recessive model: pool 12+11 --> 2x2 table

| Nb df | threshold | P- |
|-------|-----------|-------|
| | | value |
| 1 | 3,84 | 0,05 |
| 2 | 5,99 | 0,05 |
| 3 | 7,81 | 0,05 |

→ H0 rejected if p-value < 0,05
</p>

[▶] If the size of an expected category <5, use fisher exact test

EXAMPLE OF GENOTYPIC ASSOCIATION TEST

| Obs. count | Cases | Controls | total | OR | 95% <i>C</i> I |
|-------------|-------|----------|-------|----|----------------|
| Genotype 11 | 72 | 84 | 156 | - | - |
| Genotype 12 | 54 | 31 | 85 | ? | ? |
| Genotype 22 | 46 | 13 | 59 | ? | ? |
| total | 172 | 128 | 300 | | |

- => Genotypes 12 et 22 7 disease risk compared to 11 genotype
- => The risk associated to genotype 22 is x2 compared to the risk of genotype 12

• Homogeneity χ^2

| Exp. count | Cases | Controls | total |
|-------------|-------|----------|-------|
| Genotype 11 | 89.44 | 66.56 | 156 |
| Genotype 12 | 48.73 | 36.27 | 85 |
| Genotype 22 | 33.83 | 25.17 | 59 |
| total | 172 | 128 | 300 |

$$\chi^{2}(2) = 19.57$$

P-val = 0.000056

ANOTHER APPROACH: LOGISTIC REGRESSION

Dependant variable Y=1 (cases) O (controls) Independant variable X=1 (allele 2 of a SNP) O (allele 1 of a SNP)

Probability of being affected (or unaffected)

$$P = P(Y=1/X) = \exp \theta / (1 + \exp \theta)$$

$$1-P = P(Y=0/X) = 1 / (1 + \exp \theta)$$
where $\theta = \text{Logit P}$

$$= \alpha + \beta X$$

* Allelic risk (2 vs 1) estimated by the odds ratio (OR)

OR =
$$\exp(\beta)$$

95% CI = $\exp[\beta \pm 1.96*\sqrt{\text{var}(\beta)}]$

• Likelihood ratio test ($L = \prod_{i=1..n} P^{Yi} * (1-p)^{1-Yi}$; n=nb obs) $LR = -2 ln [L(\beta=0) / L(\beta max)] \sim \chi^2(1 df)$

LOGISTIC REGRESSION : EXAMPLE

| Variable | Regressive coefficient | Standard error | Ln L |
|----------|------------------------|-------------------|--------|
| baseline | -5.3 | 1.134 | -53.68 |
| SNP | 0.111 | 0.024 | 33.33 |

$$\Rightarrow$$
 Ln L(β =0) = -63.14

Likelihood ratio test

LR = -2 In [L(
$$\beta$$
=0) / L(β max)] = -2 In(L(β =0) - (-2) In(β max) = -2 * (-63.14) - (-2) * (-53.68) = 18.92 ~ χ^2 (1) => P-val = 1.36*10⁻⁵

• OR et 95% CI

OR =
$$\exp(0.111) = 1.12$$

95% CI = $\exp[\beta \pm 1.96*\sqrt{\text{var}(\beta)}] = [1.07; 1.17]$

♦ Test de Wald :
$$T = \beta / \sqrt{var(\beta)} = 0.111/0.024 = 4.61 \sim N(0,1)$$

OTHER CODING SCHEME FOR THE INDEPENDANT VARIABLE

General genotypic coding scheme ⇒ Introduction of 2 indicator variables

| Genotype | X1 | X2 | $Logit P = \alpha + \beta_1 X_1 + \beta_2 X_2$ |
|----------|----|----|---|
| 11 | 0 | 0 | ⇒ Baseline genotype |
| 12 | 1 | 0 | \Rightarrow $OR_{12 \text{ vs } 11} = exp(\beta 1)$ |
| 22 | 0 | 1 | $\Rightarrow OR_{22 \text{ vs } 11} = exp(\beta 2)$ |

Additive genotypic coding scheme ⇒ Multiplicative model => trend test

| Genotype | × | |
|----------|---|--|
| 11 | 0 | |
| 12 | 1 | \Rightarrow $OR_{12 \text{ vs } 11} = exp(\beta)$ |
| 22 | 2 | $\Rightarrow OR_{22 \text{ vs } 11} = \exp(2*\beta) = \exp(\beta)^2$ |

* Dominant or recessive coding scheme

| | Dom | Rec |
|----------|-----|-----|
| Genotype | X | X |
| 11 | 0 | 0 |
| 12 | 1 | 0 |
| 22 | 1 | 1 |

MULTIVARIATE LOGISTIC REGRESSION

* Advantage of logistic regression

To take into account other variables (genetic and/or environmental) to test association of a SNP with a disease

Logit P =
$$\alpha$$
 + $\beta_1 X_1$ + $\beta_2 X_2$... + $\beta_v X_v$

* Test of association for a SNP (X1)

$$H0: β1=0$$
 ; $H1: β1 ≠ 0$

$$OR_{adjusted for other variables} = exp(\beta_1)$$

95% CI = exp [
$$\beta_1 \pm 1.96*\sqrt{\text{var}(\beta_1)}$$
]

Selection of the best model (combination of SNPs associated with the disease) - Example: stepwise procedure


GENOME-WIDE ASSOCIATION ANALYSES

In the context of genome-wide association analyses (GWAs), since thousands of SNPs are analysed, the p-value must be corrected for multiple testing

- If p-value=5%, expected number of false positive results:
 - => on 100 tests where H0 should be true, 5 false positives
 - => on 100000 tests, 5000 false positives!
- Different methods allow to correct p-value for multiple testing the most simplest = Bonferroni correction


p-value_{Corr} = 5% / nb of independents SNP tested

Ex: if 100000 tests, p-value_{Corr} = 0.05 / 100000 = 5×10^{-7}



GENOME-WIDE ASSOCIATION STUDY FOR MELANOMA

(GenoMEL Consortium)
Bishop DT, Demenais F et al, Nat Genet, 2009



GENOME-WIDE ASSOCIATION STUDY FOR OTHER CANCERS

Easton et al, Hum Mol Genet, 2008

| Locus | Chromosome | SNP(s) | MAF | Per allele OR ^b | P-value ^e |
|-------------------|------------|--------------------------------|------|----------------------------|----------------------|
| Breast cancer | | | | | |
| 2q35 | 2 | rs13387042 | 0.50 | 1.21 | 10-13 |
| MAP3K1 | 5 | rs889312 | 0.28 | 1.13 | 7×10^{-20} |
| MRPS30 | 5 | rs10941679 | 0.25 | 1.19 | 3×10^{-11} |
| ECHDC1, RNF146 | 6 | rs2180341 | 0.27 | 1.41 | 3×10^{-8} |
| 8q24 | 8 | rs13281615 | 0.40 | 1.08 | 10-12 |
| FGFR2 | 10 | rs2981582 | 0.38 | 1.26 | 2×10^{-76} |
| LSP1 | 11 | rs3817198 | 0.30 | 1.07 | 3×10^{-9} |
| TNRC9, LOC643714 | 16 | rs3803662 | 0.25 | 1.20 | 10-36 |
| Prostate cancer | | | | | |
| 2p15 | 2 | rs721048 | 0.19 | 1.15 | 8×10^{-9} |
| 3p12 | 3 | rs2660753 | 0.11 | 1.18 | 3×10^{-8} |
| 6q25 | 6 | rs9364554 | 0.29 | 1.17 | 6×10^{-10} |
| 7g21 | 7 | rs6465657 | 0.46 | 1.12 | 10-9 |
| JÄZF1 | 7 | rs10486567 | 0.77 | 1.12 | 10-7 |
| 8q24 | 8 | rs1447295, DG8S737 | 0.10 | 1.62 | 3×10^{-11} |
| 8q24 | 8 | rs6983267 | 0.50 | 1.26 | 9×10^{-13} |
| 8q24 | 8 | rs16901979, hapC | 0.03 | 2.1 | 3×10^{-15} |
| HNF1B | 17 | rs4430796 | 0.49 | 1.24 | 10-11 |
| HNF1B | 17 | rs11649743 | 0.80 | 1.28 | 2×10^{-9} |
| 17q | 17 | rs1859962 | 0.46 | 1.25 | 3×10^{-10} |
| MSMB | 10 | rs10993994 | 0.40 | 1.25 | 9×10^{-29} |
| CTBP2 | 10 | rs4962416 | 0.27 | 1.17 | 3×10^{-8} |
| 11q13 | 11 | rs7931342 | 0.51 | 1.19 | 2×10^{-12} |
| KLK2/KLK3 | 19 | rs2735839 | 0.85 | 1.20 | 2×10^{-18} |
| Xp11 | X | rs5945619 | 0.36 | 1.19 | 2×10^{-9} |
| Colorectal cancer | | | | | |
| 8q24 | 8 | rs6983267 | 0.50 | 1.17 | 3×10^{-11} |
| SMAD7 | 18 | rs4939827 | 0.53 | 1.15 | 10-12 |
| CRAC1 | 15 | rs4779584 | 0.19 | 1.26 | 4×10^{-14} |
| EIF3H | 8 | rs16892766 | 0.07 | 1.25 | 3×10^{-18} |
| 10p14 | 10 | rs10795668 | 0.67 | 1.12 | 3×10^{-13} |
| 11g23 | 11 | rs3802842 | 0.29 | 1.10 | 6×10^{-10} |
| Lung cancer | - | | | - 1 | |
| CHRNA3/CHRNA5 | 15 | rs8034191 | 0.33 | 1.30 | 5×10^{-20} |
| Melanoma | | | | - 40- 0 | |
| TYR | 11 | rs1126809 (R402Q) | 0.30 | 1.21 | 10-7 |
| ASIP | 20 | rs1015362/ rs4911414 Haplotype | 0.08 | 1.45 | 10-9 |
| | 20 | rs910873 rs1885120 | 0.09 | 1.75 | 10-15 |


REASONS FOR A GENETIC ASSOCIATION

* The marker locus contains the causal (functional) variant

 The marker locus is in linkage disequilibrium (LD) with the locus including the functional variant

* The association is due to confounding by population stratification

EXAMPLE OF GENETIC DIVERSITY - PCA RESULTS



ASSOCIATION ANALYSES

SEARCH FOR CAUSAL VARIANTS


_

FAMILIAL ASSOCIATION ANALYSES

FAMILY-BASED ASSOCIATION STUDIES

Transmission Disequilibrium Test (TDT)

Trios: 2 parents + 1 affected offspring



Sample: N trios

Only heterozygous parents are informative

N1 = no times when A transmitted from an heterozygous to affected offspring N2 = no times when B transmitted from an heterozygous to affected offspring

H0: N1 = N2 = (N1+N2)/2 (No association or No linkage)


 $H1: N1 \neq N2$

Test: $\chi 2 = (N1 - N2)^2/(N1 + N2)$ with 1 df

if significant test => Association & Linkage

EXAMPLE

Given a sample of 100 trios of the following types



N1 = nb A transmitted from an heterozygous to affected offspring = 20 N2 = nb B transmitted from an heterozygous to affected offspring = 130

H0: N1 = N2 = (N1+N2)/2 (No association or No linkage)

 $H1 : N1 \neq N2$ (association and linkage)

Test: χ^2 (1 df) = (130 - 20)²/150 = 80,67 > 3.84

=> Association & linkage

REASONS FOR A GENETIC ASSOCIATION

* The marker locus contains the causal (functional) variant

Causal variant --> Disease

 The marker locus is in linkage disequilibrium (LD) with the locus including the functional variant

- > Advantage of family-based studies: avoids the problems of stratification that can occur with population-based studies
- > Disadvantage of family-based studies: more difficult to collect

WHAT DID I REMEMBER ? (3)













Envoyez @NJBZZS au 06 44 60 96 62




Désactiver les réponses par SMS

Genetics of Complex Diseases: Methodological Tools

PART 2

GENETIC LINKAGE ANALYSES



AIM OF A LINKAGE ANALYSIS


At the beginning :

Locating a disease gene on the genome using genetic markers (MK) whose location is known

* Today:

+ Combine linkage and association scores to identify new variants with familial data

* Example: pVAAST (Hu et al., 2014)



GENERAL PRINCIPLE OF LINKAGE ANALYSES

* Aim :

Locating a disease gene on the genome using genetic markers (MK) whose location is known

- ·To locate a Mendelian entity: lodscore method
 - > Study of disease-marker co-transmission in families
 - + <u>estimation of the recombination rate</u> between the disease gene and the MKs
- ·To locate a susceptibility gene: sib-pairs method
- Analysed data:
 - Familial sample (nuclear/3 generations) identified by affected subject and with at least 2 children
 - Including: phenotypic information + MK genotypes

PREFERENTIALLY USED MARKERS

- RFLP (Restriction Fragment Length Polymorphism)
 - The polymorphism is due to the length of the fragments
 - · di-allelic

- MICROSATELLITES
 - Tandem repeat of short nucleotide motifs
 - · Multi-allelics

Ex: (CA)n

 \triangleright The more polymorphic a marker, the more useful ("informative") it will be for estimating θ (=> MK most used= microsatellites)

GENETIC LINKAGE ANALYSES


MENDELIAN ENTITY LOCATION

_

LODSCORE METHOD

RECOMBINATION RATE ESTIMATION


- Estimation of the recombination rate θ (fct of distance) :
 - θ = nb of recombination events / total nb of events



- Steps to estimate θ :
 - 1) Establish the phenotype \Leftrightarrow genotype relationship to assign disease gene genotypes in families
 - 2) Determine the allelic phase in double-heterozygous parents (only informative subject to follow gene-MK segregation)
 - 3) For each child, establish whether a parental or recombinant gamete was transmitted by the double-heterozygous parents


EXAMPLE n°1: DIRECT ESTIMATE OF θ

- Genetic model:
 - Autosomal dominant disease
 - di-allelic gene (M=deleterious; m=wild-type) P(affected/MM)=1 P(affected/Mm)=1 P(affected/mm)=0
- Example n°1: Estimation of θ possible directly



EXAMPLE n°2: ESTIMATION OF θ IMPOSSIBLE DIRECTLY


• Example n^2 : θ cannot be calculated directly



Genetic model identical to example n°1



Non-informative mother



Allelic phase of the father: indeterminate

Phase 1: A1m/A2M (proba $\frac{1}{2}$)

Phase 2: A1M/A2m (proba $\frac{1}{2}$)

Types of γ transmitted by father under phase 1 Types of γ transmitted by father under phase 2

LOD-SCORE TEST (Morton, 1955)


- + Aims
 - Test if 2 loci are genetically linked or not
 - Estimate the recombination rate
- Assumptions tested
 - HO: Absence of genetic linkage (θ =0.5)
 - H1: Genetic linkage for estimated θ (0 $\leq \theta$ <0,5)
- \bullet Calculation of the Lod-score for a family Fi and a given value of θ

$$Z_{i}(\theta_{1}) = \log_{10} \frac{P(F_{i}/\theta_{1})}{P(F_{i}/\theta=0,5)} = \log_{10} \frac{L_{i}(\theta_{1})}{L_{i}(\theta=0,5)}$$

where $L_i(\theta_1) = \Sigma_{phases} P(phase) \times L_{i,phase}(\theta_1)$ and $L_{i,phase}(\theta_1) = \Pi_{nb \ enf} P(father \ gamete) \times P(mother \ gamete)$

EXAMPLE OF LIKELIHOOD CALCULATION

Non-informative mother



Allelic phase of the father: indeterminate

Phase 1: A1m/A2M (proba $\frac{1}{2}$)

Phase 2: A1M/A2m (proba $\frac{1}{2}$)

Types of γ transmitted by father under phase 1


Types of γ transmitted by father under phase 2

- Under phase 1: $L_{i,phase1}(\theta) = (\theta/2)^1 \times [(1-\theta)/2]^4$
- Under phase 2: $L_{i,phase2}(\theta) = (\theta/2)^4 \times [(1-\theta)/2]^1$
- ightharpoonup Conclusion: $L_i(\theta) = \frac{1}{2} (\theta/2)^1 \times [(1-\theta)/2]^4 + \frac{1}{2} (\theta/2)^4 \times [(1-\theta)/2]^1$

$$L_i(\theta) = (\frac{1}{2})^6 \times \theta \times (1-\theta) \times [(1-\theta)^3 + \theta^3]$$

EXAMPLE OF LOD-SCORE CALCULATION

Mère non informative



Allelic phase of the father: indeterminate

Phase 1: A1m/A2M (proba $\frac{1}{2}$)

Phase 2: A1M/A2m (proba $\frac{1}{2}$)

Types of γ transmitted by father under phase 1

Types of γ transmitted by father under phase 2

$$L_i(\theta) = (\frac{1}{2})^6 \times \theta \times (1-\theta) \times [(1-\theta)^3 + \theta^3]$$

$$Z(\theta) = \log \left[\frac{(\frac{1}{2})^6 \times \theta \times (1-\theta) \times [(1-\theta)^3 + \theta^3]}{(\frac{1}{2})^6 \times \frac{1}{2}^2 \times (\frac{1}{2})^2} \right]$$

$$Z(\theta) = \log [2^4 \times \theta \times (1-\theta) \times [(1-\theta)^3 + \theta^3]]$$

THRESHOLDS TO CONCLUDE

* Calculation of the Lod-score in a sample of n families

•
$$Z(\theta) = \sum_{i=1}^{n} Z_{i}(\theta)$$

- Find the value of θ that maximizes the Lod-Score (estimated $\theta_{\text{max}})$ in the total sample
 - + calculation of $Z(\theta)$ for given θ

Thresholds

- if $Z(\theta_{max}) \ge 3$ \Rightarrow H0 rejected => linkage for θ_{max}
- if $Z(\theta_i) \le -2$ absence of genetic linkage for $\theta_i (\theta_i \ne \theta_{max})$
- if $-2 < Z(\theta_{max}) < 3$ \Rightarrow nothing can be concluded (families must be added to the analysed sample)

Propriétés statistiques

Morton a montré que pour de tels critères :

• erreur de première espèce α = proba (rejeter H0 / H0 vraie)

$$\alpha \leq 10^{-3}$$

erruer de seconde espèce β = proba (rejeter H1 / H1 vraie)

$$\beta \leq 10^{-2}$$


- fiabilité ρ = proba (H0 vraie / on a conclu H1)
- = probabilité que la liaison n'existe pas alors que z(θ1) a dépassé 3

$$\rho \leq 0.05 \forall \theta 1$$

• puissance $P(\theta 1)$ = proba (rejeter H0 / θ est la vraie valeur)

 $P(\theta) \ge 0.80 \ \forall \theta 1$ si la vraie valeur de $\theta < 0.10$


EXAMPLE OF INTERPRETATION OF A LOD-SCORE RESULT



$$Z(\theta) = \log [2^4 \times \theta \times (1-\theta) \times [(1-\theta)^3 + \theta^3]]$$


- \bullet Estimation of θ maximizing the lod-score
 - Performed using analysis software (LINKAGE)
 - θ_{max} = 0,212 et Z(0,212)=0,12
- Conclusion
 - -2 < $Z(\theta_{max})$ <3 => nothing can be concluded
 - > families must be added to the sample

CONFIDANCE INTERVAL



EXAMPLES OF LOD-SCORE CURVES

Genetic linkage is excluded for all $\theta \le \theta_1$ if there is a value of θ_1 such that $Z(\theta_1) = -2$



RESULTS OF A LINKAGE ANALYSIS ON A FAMILIAL SAMPLE

 θ : 0.0 0.1 0.2 0.3 0.4 0.5

| 1=2 | -infini | 21.71 | 18.00 | 13.14 | 7.21 | 0.00 | |
|-----|---------|-------------|-------|-------|-------------|------|--|
| 1 | -infini | 2.24 | 2.28 | 1.82 | 1.06 | 0.00 | |
| 2 | -infini | 4.15 | 3.48 | 2.55 | 1.41 | 0.00 | |
| 3 | 6.02 | 5.11 | 4.08 | 2.92 | 1.58 | 0.00 | |
| 4 | 6.02 | 5.11 | 4.08 | 2.92 | 1.58 | 0.00 | |
| 5 | 6.02 | 5.11 | 4.08 | 2.92 | 1.58 | 0.00 | |
| 6 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |

Z values in the total sample

Z values per family (here 6 families)

- > Z(0)=-infini --> at least 1 recombination is observed
- > The disease locus is approximately located 10cM from the MK
- > Families 3, 4 and 5 have the same lodscore
- \triangleright Family 6 is not informative (L does not depend on θ)
 - --> there is no double heterozygous parent

WHAT DID I REMEMBER ? (4)













Envoyez @QLRXDY au 06 44 60 96 62



Désactiver les réponses par SMS

CONDITIONS OF APPLICATION AND DISADVANTAGES OF THE LOD-SCORE METHOD

- * Lod-score method = model-dependent approach
 - > The genetic model must be known
 - > If genetic model unknown, the parameters (allelic freq., penetrances, transmission mode) can be estimated with recombination rate
 - -> thresholds ?
- Impact of an error on used parameters
 - > If genetic model of the disease not well known
 - -> power loss, false exclusion possible
 - > If error on marker allele frequency
 - -> risk of false positives

ANALYSIS PROGRAMS

- * Rockefeller website
 - allows to download genetic analysis software for free
 - http://linkage.rockefeller.edu/soft/


- Bi-point genetic linkage analysis programs
 - MLINK : calculates values of Z for \neq values of θ
 - LODSCORE : calculates Z_{max} associated with θ_{max}
- * Multi-point genetic linkage analysis programs
 - LINKMAP ou CMAP: Locate a disease locus in relation to a set of MKs (established genetic map)
 - > These programs can be used to establish genetic maps

PRINCIPLE OF MULTIPOINT ANALYSIS

* Idea:

From the genetic map established for a certain number of MK, we vary the position of the disease gene and we conclude with respect to the most likely location

◆ Example: use of a genetic map with 3 MK (M1, M2, M3)



Calculation of the multipoint lod-score at each position Xi : log10 [L(Xi)/L(I)]

THRESHOLDS


Genetic linkage

- If for a given location the multipoint lod score is greater than 3 and included in the CI
 - --> possible location of disease gene
- Its probable location is the position for which the lod-score is maximum

Linkage rejected

 We can also reject regions for which the multipoint lod-score is less than or equal to -2

EXAMPLE OF MULTI-POINT CURVE



EXAMPLE OF USE OF LOD-SCORE TO LOCATE MENDELIAN ENTITIES

Breast cancer

- 1st gene localised in 17q21 (Hall et al 1990) → BRCA1
- 2nd gene localised in 13q12 (Wooster et al 1994) \rightarrow BRCA2
- other genes...

◆ Melanoma

- localised gene in 9p21(Cannon-Albright et al 1992) \rightarrow CDKN2A
- other genes : CDK4, 1p, others?

LINKAGE ANALYSES AND MULTIFACTORIAL DISEASES

Multifactorial diseases

Multifactorial human diseases most often result from complex interactions between genetic and environmental factors

* Genetic model for multifactorial diseases

We cannot explain the transmission of the disease by a simple model (unless Mendelian entity (MG for Major Gene))

- the Lod-score method (model-dependent method) cannot be used to locate disease genes (except MG)
- It is necessary to use model-independent methods
 - -> method of affected sib pairs (binary traits)

GENETIC LINKAGE ANALYSES

SUSCEPTIBILITY GENE LOCATION

-

AFFECTED SIB-PAIRS METHOD

AFFECTED SIB-PAIRS METHOD

+ Aim


Locate a gene involved in a disease without a priori knowledge of its genetic model

Principle

Related subjects (siblings) resembling each other phenotypically (affected) do they resemble each other for the genotypes of the marker?

If yes \rightarrow genetic linkage


* Sample




Calculation of the IBD variable (IBD=Identity By Descent) for the 2 affected sibs

IBD: IDENTITY BY DESCENT

Two alleles present in two related individuals are IBD (identical by descent) if they both come from the same common ancestor



EXPECTED PROPORTIONS OF IBD IF NO LINKAGE



The different possible genotypes for O1 and O2 are shown in the right table with the associated IBD status

| G_{01} | A1A3 | A1A4 | A2A3 | A2A4 |
|----------|------|------|------|------|
| A1A3 | 2 | 1 | 1 | 0 |
| A1A4 | 1 | 2 | 0 | 1 |
| A2A3 | 1 | 0 | 2 | 1 |
| A2A4 | 0 | 1 | 1 | 2 |

Note: whatever the genotypes of the parents, we always obtain the table above

| IBD Status | 0 | 1 | 2 |
|----------------------|----------|----------|----------|
| Expected proportions | 4/16=1/4 | 8/16=1/2 | 4/16=1/4 |

OF AFFECTED SIBS (Penrose 1935)

| | IBD | | |
|----------------------------|-----|-----|-----|
| | 0 | 1 | 2 |
| Expected counts (under H0) | N/4 | N/2 | N/4 |
| Observed counts | n0 | n1 | n2 |

N: total number of sib pairs = n0+n1+n2

nO, n1, n2: number of pairs sharing 0, 1 or 2 alleles


HO: no genetic linkage [P(IBD=0)=25%; P(IBD=1)=50%; P(IBD=2)=25%]


H1: genetic linkage [P(IBD=0)+25%; P(IBD=1)+50%; P(IBD=2)+25%]


Test: $\chi^2 = \Sigma ((O-E)^2/E)$ with df=2

EXAMPLE OF CALCULATION OF THE LINKAGE TEST BASED ON THE IBD STATUS OF AFFECTED SIBS

Analysed sample: 100 affected sib-pairs / 1 marker with 4 alleles (a, b, c et d)







| | IBD | | |
|-------------|-----|----|----|
| | 0 | 1 | 2 |
| Exp. counts | 25 | 50 | 25 |
| Obs. Counts | 20 | 30 | 50 |

HO: no genetic linkage


H1: genetic linkage


Test: χ^2 (2 df) = 34 > 5.99

> H0 rejected --> genetic linkage

UNCERTAINED IBD STATUS

Examples of families with uncertained IBD status:





IBD = 1 ou 2 ?

Other methods if uncertained IBD status :

MLS (Maximum Likelihood Score) or NPL (Non Parametric Linkage)

ADVANTAGES-DISADVANTAGES SIB-PAIRS METHOD VS LOD-SCORE METHOD

Advantages :

- · conceptually simple
- fast computing time
- no specification of the genetic model

Disadvantages :

- less powerful methods
- one cannot obtain an estimate of the recombination rate (therefore less precise)

WHAT DID I REMEMBER ? (5)













Envoyez @PKPEUY au 06 44 60 96 62



Désactiver les réponses par SMS

Use of haplotypes to localise disease gene


Autosomal dominant disease

Search for haplotypes


common to affecteds

III-3 & III-6 received recombinant gametes from their affected mother.

The disease gene is located between markers B and D.



AND AFTER ...



♦ What is the causal variant?

Genetics of Complex Diseases: Methodological Tools

PART 3

SEARCH FOR INTERACTIONS

Exemple: gene-environment interaction

E+

E
G1


E
G2

G2

G3

INTERACTION GXE

G and E do not act independently on the development of the disease but interact (the response to E will depend on G)



INTERACTION TEST: Q-TEST

Stratum 1: E+

| | Cases | Controls | total |
|----------|-------|----------|-------|
| Allele 1 | α1 | b1 | R11 |
| Allele 2 | c1 | d1 | R12 |
| total | C11 | C12 | T1 |

Stratum 2 : E-

| | | • – | |
|----------|-------------|----------|-------|
| | Cases | Controls | total |
| Allele 1 | a 2 | Ь2 | R21 |
| Allele 2 | c2 | d2 | R22 |
| total | <i>C</i> 21 | C22 | T2 |

$$ightharpoonup OR_i = \frac{a_i d_i}{b_i c_i}$$

→ Homogeneity test for k strata (H0 : ORi= ; H1: ORi≠)

$$\chi^{2}(k-1) = \sum w_{i}^{*}(\ln(OR_{i})-Y)^{2}$$

For stratum i :

$$w_i = 1/\text{var}(\ln(OR_i))$$

 $Y = [\Sigma w_i * \ln(OR_i)] / \Sigma w_i$

INTERACTION TEST: EXAMPLE

| Stratum 1 : E+ | | | |
|----------------|-------|----------|-------|
| | Cases | Controls | total |
| Allele 1 | 6 | 16 | R11 |
| Allele 2 | 48 | 322 | R12 |
| total | C11 | C12 | T1 |

$$OR_1 = 2.52$$

 $Ln(OR_1) = 0.9225$
 $w_1 = 3.95$

| / | 51 | tratum | 2 : E- | • |
|---|----------|-------------|----------|-------|
| | | Cases | Controls | total |
| | Allele 1 | 14 | 4 | R21 |
| | Allele 2 | 25 | 56 | R22 |
| | total | <i>C</i> 21 | C22 | T2 |

$$OR_2 = 7.84$$

 $Ln(OR_2) = 2.059$
 $w_2 = 2.636$

 \triangleright Homogeneity test for k=2 strata (H0: $OR_1 = OR_2$; H1: $OR_1 \neq OR_2$)

$$\chi^{2}(k-1) = \Sigma w_{i}^{*}(\ln(OR_{i})-Y)^{2}$$

 $\chi^{2}(1) = 2.04$
P-val = 0.15

For stratum i :

$$w_i=1/\text{var}(\ln(OR_i))$$

 $Y = [\Sigma w_i^*\ln(OR_i)] / \Sigma w_i$

INTERACTION TEST BY LOGISTIC REGRESSION (1)

P(affected / G,E) = P =
$$\frac{\exp(\alpha + \beta_G G + \beta_E E + \beta_I G \times E)}{(1 + \exp(\alpha + \beta_G G + \beta_E E + \beta_I G \times E))}$$

Logit P = log (P/1-P) =
$$\alpha + \beta_G G + \beta_E E + \beta_I I$$

Coding of variables

$$I=G\times E=1$$
 if $G=1$ & $E=1$ 0 otherwise

- > Other risk factors may be included in the logistics model
- > To test a Gene-Gene interaction, I=GxG

INTERACTION TEST BY LOGISTIC REGRESSION (2)

Logit P =
$$\alpha + \beta_G G + \beta_E E + \beta_I I$$

- GxE interaction tests (H0 : β_{I} =0 ; H1 : $\beta_{\text{I}} \neq$)
 - Wald Test: $(\beta_T 0)^2 / Var(\beta_T) \sim \chi^2(1 df)$
 - Likelihood Ratio Test : -2ln[$L(\beta_T=0)/L(\beta_T)$] ~ $\chi^2(1 df)$
 - > Sometimes, it is more powerful to test the effects of G and I together
- * Effect of G according to exposure to E:
 - Effect of G for E+ subjects : $OR_{GE} = exp(\beta_G + \beta_I)$
 - Effect of G for E- subjects : $OR_G = exp(\beta_G)$
 - \triangleright If no interaction ($\beta_1 \approx 0$), effect of G similar for E+ and E- subjects

WHAT DID I REMEMBER ? (6)













Envoyez @GRMSHI au 06 44 60 96 62



Désactiver les réponses par SMS